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Background: Studies of alternative mRNA splicing (AS) in health and disease have yet to yield the complete
picture of protein diversity and its role in physiology and pathology. Some forms of cancer appear to be associated
to certain alternative mRNA splice variants, but their role in the cancer development and outcome is unclear.
Methods: We examined AS profiles by means of whole genome exon expression microarrays (Affymetrix GeneChip 1.0)
in ovarian tumors and ovarian cancer-derived cell lines, compared to healthy ovarian tissue. Alternatively spliced
genes expressed predominantly in ovarian tumors and cell lines were confirmed by RT-PCR.
Results: Among several significantly overexpressed AS genes in malignant ovarian tumors and ovarian cancer cell
lines, the most significant one was that of the zinc finger protein ZNF695, with two previously unknown mRNA
splice variants identified in ovarian tumors and cell lines. The identity of ZNF695 AS variants was confirmed by
cloning and sequencing of the amplicons obtained from ovarian cancer tissue and cell lines.
Conclusions: Alternative ZNF695 mRNA splicing could be a marker of ovarian cancer with possible implications
on its pathogenesis.
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Ovarian Cancer (OC) is the sixth most prevalent form of
cancer worldwide, which has a high mortality rate because
at the time of diagnosis nearly 70% of cases are at an
advanced stage, leading to a 5 year survival below 30% [1].
The classification of OC depends on its cellular origin, with
approximately two-thirds belonging to the epithelial serous
type [2]. Similar to other types of cancer, OC is characterized
by changes in gene expression profiles [3-6], including under
and overexpression, or even de novo gene expression [7,8].
Alternative splicing (AS) provides a critical and flexible
layer of regulation, intervening in many biological pro-
cesses, such as the diversity of proteins.* Correspondence: vazquezortizg@niiddk.nih.gov; jmoreno49@gmail.com
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distribution, and reproduction in any mediumAS has major impact on the cell phenotype as a single
pre-mRNA spliced in different ways can give rise to differ-
ent mature mRNA transcripts (variants) that are translated
onto distinct proteins varying in functions [9-11]. Appar-
ently, over 90% of human genes have two or more splice
variants [9,10], greatly increasing the complexity of both
the transcriptome and the proteome [12,13]. Therefore,
AS could play an important role in gene regulation both
in health and disease. In cancer, AS could affect the
cellular processes related to tumor progression, including
inhibition of apoptosis, tumor invasiveness, metastasis and
angiogenesis [14].
Among the genes with well established AS patterns
whose derived alternative proteins affect tumor cell be-
havior is the SRPK1 kinase that in breast, colonic and
pancreatic carcinomas phosphorylates the splicing factor
SF2/ASF, allowing import to the nucleus, where it modu-
lates AS of multiple target mRNAs, such as BIN1, S6K1,
MNK2, contributing to tumor progression [15,16]. Add-
itional cancer types with apparent alterations of alternativeCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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[17], hepatocarcinoma [18], prostatic cancer [19,20], mul-
tiple myeloma [21], breast cancer, and OC [22], where most
cancer-associated transcript variants belong to genes related
to processes such as cellular transformation [23,24], adhe-
sion, proliferation, migration and invasion [25-28]. In OC, a
new, previously unknown, variant of p53 mRNA transcript
variant (p53δ) was identified [29] whereas variants of the
NR4A1, a nuclear receptor involved in steroidogenesis, and
MRRF, a mitochondrial protein, were identified in prostatic
cancer [20]. Although the extent and pathophysiological
meaning of this has yet to be established, there is little
doubt that the study of alternative splicing can lead to a
better understanding of the mechanisms of cancer de-
velopment, and to the identification of new biomarkers
for the diagnosis, epidemiological studies of prevalence,
prognosis, and therapeutic responses.
The aim of the present study was to identify the whole
genome profile of alternatively spliced mRNA in ovarian
cancer and cell lines by high-density microarrays. Among
the spectrum of several ovarian cancer-associated alterna-
tively spliced genes, one mRNA, coding for ZNF695, a zinc
finger protein, had the most significantly overexpression in
OC with two prominent splice variants that were not
present in normal ovarian tissue. These variants were
cloned and sequenced. Here we describe some of the
characteristics of ZNF695 mRNA splicing variants as-
sociated to ovarian cancer.
Methods
Data set and specimens
All investigations were performed in accordance with
the Declaration of Helsinki with approval by the Central
Research Committee of the Mexican Institute of Social
Security and The Ethics Committee of Centro Médico
Siglo XXI, Mexican Institute of Social Security. After
informed consent was obtained, normal ovarian tissue
(HOT), borderline ovarian tumor (BOT), malignant epithe-
lial ovarian tumors stages III and IV (MOT) tissues were
collected by the clinical partners at the Oncology Hospital,
National Medical Center Siglo XXI, IMSS, and at the
General Hospital of Mexico SSA (Secretaría de Salud)
from patients with diagnosed ovarian cancer, or healthy
ovarian tissue from patients who underwent abdominal
surgery for hysterectomy due to uterine myomatosis with
no evidence of ovarian pathology. Routinely, during this
type of procedure, in patients over 45 years old both ovaries
are removed, and only one in patients under 45.
Cancer and corresponding normal tissue specimens were
cut into three fragments and snapped frozen in liquid
nitrogen, one of which was stored in RNA LatterR (Qiagen,
Valencia, CA, USA) at −70°C for a maximum of two months
until RNA was purified, and the other two remaining
fragments were formalin-fixed, paraffin-embedded, sliced,mounted on slides, and stained with HE. Only tissue
samples with >80% tumor cells or normal epithelial cells
(MOT or HOT, respectively), according to the histopatho-
logical examination were included for analysis.
Moreover, we also included for study ovarian cancer
cell lines (OCL) NIH: OVCAR-3 [30], SK-OV-3 [31], TOV-
112D [32] and TOV-21G [32], kindly provided by Dr. Laura
Díaz-Cueto, Research Unit on Reproductive Medicine,
Instituto Mexicano del Seguro Social (IMSS).
Samples were disrupted using a TissueLyser™ system
(Qiagen, Valencia, CA, USA) for 60s at 30 Hz. Total RNA
was obtained with RNeasy Mini Kit (Qiagen, Valencia,
CA, USA) and total RNA concentration was quantified
using a NanoDrop ND-1000 spectrophotometer and
RNA quality was visualized and measured on an Agilent
RNA 6000 Nano Assays in an Agilent 2100 Bioanalyzer
(Agilent Technologies, Santa Clara, CA, USA).Microarray GeneChip 1.0 assay
The microarray used for these studies was Affymetrix
GeneChip 1.0, which contains over 750,000 probe sets
representing all exons of ~28,800 annotated genes. Sample
amplification and preparation for microarray hybridization
was performed according to Affymetrix specifications
(http://media.affymetrix.com/support/downloads/manuals/
wt_expressionkit_manual.pdf). In brief, 100 ng total RNA
was reverse transcribed to cDNA, amplified by in vitro
transcription and reverse transcribed to cDNA again.
Fragments between 40 and 70 bp were generated enzy-
matically, labelled and hybridized onto the microarray
chips in an Affymetrix hybridization oven at 60 rpms,
45°C for 17 hours. Chips were washed according to the
established protocols (Affymetrix, Santa Clara, CA, USA)
with GeneChip fluidics station 450, and finally they were
scanned with an Affymetrix 7G GeneChip scanner. The
raw data (CEL files) will be deposited in Gene Expression
Omnibus (GEO).Data analysis
Microarray analysis was achieved by means of CEL
files of the Partek Genomics Suite 6.5 v software (Partek
Incorporated, Saint Louis, MO). Probe sets were sum-
marized by means of Median Polish and normalized by
quantiles with no probe sets excluded from analysis.
Background noise correction was achieved by means
Robust Multi-chip Average (RMA) and data were log2
transformed. Data grouping and categorization was
achieved by principal component analysis (PCA). Differ-
entially expressed exons were detected by means of Alter-
native Splicing ANOVA with the healthy control samples
as the baseline. Moreover, BOT, MOT and OCL were also
examined against HOT by the Geometric least squares
means model. Hierarchical clustering was based on the
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Reverse transcription PCR
For linear cDNA synthesis, 1 μg total RNA was predigested
with 1 U DNAse, 1 ×DNAse buffer, 5 mM EDTA, after
which it was incubated at 37°C for 30 min and at 65°C for
an additional 10 min. Thereafter, samples were placed in
master mix containing: 40 U Ribolock RNAse inhibitor,
0.2 μg random hexamer primers, 20 mM dNTP’s mix,
40 U M-Mulv reverse transcriptase (RT), and 1 ×M-Mulv
RT Buffer (Thermo Scientific).
Conditions for endpoint PCR amplification were:
5′ CGAATGAGAGCTGGCAAAGGCAAA 3′ Fwd., 5′
ACGCCAAGTGCCGTACAATTCATC 3′ Rev. primers
(housekeeping gene RPL4) 7.5 mM, 1 × Taq buffer, 2 mM
MgCl2, 0.4 mM dNTP’s, 1.25 U Taq Pol, 2 ul cDNA;
whereas ZNF695 was amplified with primers: 5′ GCCT
TTGTCTCCTTGCGGC 3′ Fwd. 5′ GGCTGTCTTCTCT
GTGTTCACGTT 3′ Rev. 12.5 mM, 1 ×Taq buffer, 3 mM
MgCl2, 0.4 mM dNTP’s, 1.25 U Taq Pol, 2 ul cDNA. In
both cases mix reactions were initially incubated at 95°C
for 5 min, and then were run for 40 cycles at 94°C 45 s,
59°C 45 s, 72°C 60 s; and finally at 72°C for 5 min.
PCR product purification and cloning
PCR products were separated by electrophoresis (2.5% agar-
ose gels) and extracted by means of Gel extraction kitTM
(Qiagen, Valencia, CA, USA). The extracted products were
ligated into pGem-T Easy Vector™ (Promega, Madinson,
WI) by incubating overnight in 1.5 mL Eppendorf tubes
with 2 × Rapid Ligation Buffer (T4 ligase), pGEM-T Easy
Vector, PCR product and T4 DNA ligase at 4°C.
Recombinant plasmid DNA was purified with Wizard
Plus Miniprep DNA Purification System™ (Promega) and
selected clones were sequenced with M13 oligonucleotide
and BigDye Terminator 3.1 cycle sequencing kit (Applied
Biosystems), and sequenced in an Applied Biosystems
Abi Prism 3130 genetic analyzer automated sequencer.
Subsequently, the PCR amplicon sequences were assembled
and checked against the transcript sequences annotated in
the NCBI nucleotide database.
Results
Expression microarray assays
A total of 14 samples with an RNA integrity number
(RIN) ≥ 8 were hybridized in GeneChip 1.0 microarrays
according to the MIAME guidelines. Histopathological
classification of tissues was as follows: healthy ovarian
tissue (HOT) n = 4, benign ovarian tumors (BOT) n = 2,
(malignant) serous epithelial ovarian tumors in stages III
and IV (MOT) n = 4, and ovarian cell lines (OCL) n = 4.
As a prerequisite, healthy tissue had to be free of any
visible alteration, whereas all tumor tissues, benign ormalignant, selected for study contained at least 90%
tumor cells.
Background correction and normalization of microarrays
reported no quality control errors (QC) and, as expected,
the QC intergroup proportions were variable (Additional
file 1), whereas gene expression histograms were similar in
all samples. General gene expression was examined and
visualized according to the histological groups by means
of PCA. As expected, except for HOT and BOT that es-
sentially overlapped, MOT and OCL clustered in distinct
regions of the PCA plot (Figure 1). Thus, HOT and BOT
clustered together in the negative end, whereas MOT and
OCL clustered separately in the positive area. This indi-
cates that our data set has the power to discriminate OC
(both MOT and OCL) from normal tissue or benign tu-
mors. Moreover, as expected, OC gene expression profiles
show a wide dispersion, reflecting tumor heterogeneity.
In contrast, HOT and BOT plotted in relatively close
proximity, even at the level of individual samples that
for the two BOT samples practically overlapped. Finally,
as expected, HOT also had some individual sample vari-
ability, probably reflecting proportional differences of
tissue contents, individual variability or variations in the
estrous stage, neither of which was addressed.
Moreover, hierarchical clustering on the basis of relative
gene expression also grouped HOT and BOT together,
whereas malignancies (both MOT and OCL) clustered
together but distant of HOT and BOT (Figure 2). None-
theless, careful analysis of individual genes revealed some
small intragroup differences that could reflect tumor
heterogeneity and that deserves further in depth analysis.
Interestingly, predominant OC-associated changes in gene
expression were suppression rather than overexpression
(Additional file 2).
Up to here, the results show two major ovarian tissue
gene expression patterns, one specific of OC (cell lines and
tumors) and the other one characteristic of borderline tu-
mors and healthy tissue. The gross differences seen probably
reflect the relatedness among the different groups. To fur-
ther explore this, we compared gene expression by grouping
apparently related conditions together, against each of the
individual or grouped opposites (Table 1). By these means,
the highest differences were MOT + OCL vs. BOT + HOT
(n = 1799), followed by MOT + OCL vs. HOT (1498 differ-
ences), MOT + OCL vs. BOT (1030 differences), BOT +
MOT + OCL vs. HOT (545 differences). Finally, gene ex-
pression differences between BOT and HOT were minimal
(~28). On the basis of these findings, we chose to further
examine the most significant differentially expressed exons.
Exon analysis identifies two major ovarian cancer-associated,
differentially spliced transcripts of gene ZNF695
Once we had examined the relative OC-associated gene
expression profiles, it was important to examine whether
Figure 1 Overlapping gene expression patterns in healthy ovary and benign tumors that differ from ovarian cancer. Principal
component analysis (PCA) depicting gene expression profiles of healthy (HOT, green), benign ovarian tumors (BOT, red), tumor (MOT, purple) and
ovarian cell lines (OCL, blue).
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tive differences or if there were also qualitative differences
among them. To achieve this, we performed exon analysis
of genes overexpressed in both MOT and OCL. As differ-
ential exon usage cannot be easily examined in suppressed
genes, we exclusively examined overexpressed genes.
The analysis was performed by means of Alternative
Splicing ANOVA and the criteria to select genes for
exon analysis were: false discovery ratio (FDR) < 0.05 and
fold change >3, in at least one probe set. According to these
criteria, the number of overexpressed alternatively spliced
genes in OC was 207 (Additional file 3). To identify OC-
predominant splice variants, these genes were subjected
to internal analysis by comparing the expression of each in-
dividual exon for each study group against the mean total
expression of the same gene in each of the groups, and
were considered only when they yielded ≥3 fold change.
Moreover, we performed visual inspection of each of the
individual exon expression profile graphs (MOT + OCL
vs. HOT + BOT or vs. HOT or vs. BOT, all of which
yielded the same genes). This procedure identified at
least nine genes of potential interest (Table 2), of which,
ZNF695 (encoding a zinc-finger protein) had the highestoverexpression (~7 fold, FDR < 0.005) in MOT and OCL,
and its mRNA had the highest significant changes in exon
expression with significant suppression in one its exons
when compared to HOTand BOT (Figure 3). The remaining
of this study focuses on the characterization of ZNF695.
ZNF695 splice variants in OC
ZNF695 encode a zinc finger protein with as yet un-
known functions and its gene contains six exons located
in chromosome 1q cytogenetic positions 247,148,625-
247,171,358. This gene has six possible transcripts of
which two (ZNF695-003, and ZNF695-006) encode
complete ORFs yielding a 515 and a 172 amino acid
length proteins, respectively; whereas the other four
transcripts encode products thought to undergo nonsense-
mediated decay, a process that detects nonsense mutations
and prevents the expression of truncated transcripts
(http://www.ensembl.org/Human/Search/Results?q=ZNF6
95;site=ensembl;facet_species=Human).
To characterize transcripts expressed predominantly
in OC, we designed primers to identify and clone splice
variants of ZNF695 most likely corresponding to the mes-
sage lengths preferentially expressed in the four initial OC
Figure 2 Hierarchical clustering of ovarian cancer gene. Heat maps depicting hierarchical clustering of gene expression in healthy ovarian
tissue, benign ovarian tumours, ovarian cancer and ovarian cancer cell lines. Graphics were generated by means of Partek Genomics Suite™
software. Differentially expressed gene values were included only when fold-change was > 3 and false discovery ratio < 0.005 and only the
number of genes clustering to over- expression (top), no significant changes (middle) and under-expression (bottom) are shown. Gene names,
RefSeq, and other details are shown in Additional file 2.




BOT vs. HOT 28 24 4
MOT vs. HOT 1329 476 853
OCL vs. HOT 1664 669 995
MOT vs. BOT 625 135 490
OCL vs. BOT 1369 488 881
OCL vs. MOT 666 385 281
BOT + MOT + OCL vs. HOT 545 146 399
MOT + OCL vs. HOT 1498 508 990
MOT + OCL vs. BOT 1030 262 768
HOT + MOT + OCL vs. BOT 368 28 340
MOT + OCL vs. BOT + HOT 1799 595 1205










MOT vs. BOT and HOT)
9 ZNF695 1.28E-05 8.16E-05 4.5411
13 CCNB1 3.11E-06 2.26E-10 4.98751
36 FANCD2 4.87E-05 8.33E-10 6.58464
12 CDKN3 2.51E-04 7.59E-10 5.42259
25 TPX2 1.05E-04 2.04E-16 11.0438
14 E2F8 1.27E-03 1.92E-07 3.20517
14 FOXM1 1.09E-04 2.98E-08 5.86201
18 HMMR 1.71E-03 3.87E-02 6.55569
50 CENPE 1.87E-03 5.00E-05 4.35735
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Figure 3 Differential ZNF695 exon usage in ovarian cancer. A) All possible splice variants of zinc finger protein (ZNF) 655 mRNAs retrieved
from UCSC Genome Browser. B) Graphic depicting levels of individual exon expression in healthy ovarian tissue (HOT, green), benign ovarian
tissue (BOT, red), malignant ovarian tumours (MOT, purple) and ovarian cancer cell lines (OCL, blue). C) Heat map of each of the peaks containing
the individual samples.
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(10 MOT and four OCL), expression of the three different
transcripts was as follows: seven out of 10 tumor samples
and three out of four cell lines expressed all three tran-
scripts at variable degree, whereas the remaining sam-
ples (three tumors and one cell line) only expressed
the two larger transcripts (Figure 4A and B). All three
amplicons were gel purified, cloned into pGEM-T Easy
Vector (Figure 5A) and confirmed to correspond to the
aforementioned ZNF695 RNA transcripts by sequencing
(Figure 5B-E). The first one appears to correspond to the
full-length product (FLP), as it yields a 400 bp amplicon
spanning FLP nucleotides 38 to 433 with full identity to
ZNF695-003, ZNF695-006 and no other possible match
(Figure 5B-C, Additional file 4). The second transcript
spans 360 bp (that we name here ZNF695 transcript 4,
see below) fully matching ENSEMBL nonsense-mediated
decay transcript ZNF695-002, as well as NCBI peptide
BAG54313.1 (Isogai, T. Helix Research Institute, Genomics
Laboratory; e-mail: flj-cdna@nifty.com, http://www.ncbi.nlm.
nih.gov/protein/193785160?from=1&to=118) (Figure 5B, E,Additional file 5). The third transcript (named here ZNF695
transcript 5) found here aligns with both those transcripts
up to nucleotide 361, but our primers cannot identify
further on the 5’ direction. Although we cannot tell to
which of ZNF695 splice variants it corresponds, this tran-
script contains a sequence partly identical to ZFN695-002
(ZNF695 transcript 4), except that it is missing a 52 bp
fragment containing part of the 5’ untranslated region
and misses the translation initiation signal (Figure 5D, E,
Additional file 4). Although there are additional AUG
codons as potential alternative translation initiation
signals 3’ of the canonical AUG, these fail to yield useful
ORFs. Therefore, most likely, this transcript represents
a long non-coding mRNA. Finally, Figure 5F shows the
ZNF695 AS model according to the transcripts found in
MOT and OCL.
Discussion
Understanding the origin of malignancy is one of the
greater challenges of modern science. Among malignant
tumors, OC represents a major problem because little is
Figure 4 ZNF695 transcripts of healthy ovarian tissue, individual ovarian cancer samples, and cell lines. A) Agarose gel showing the
raw RT-PCR products obtained from one HOT (n = 6) sample and MOT (n = 7) samples. Above, RPL4 protein (housekeeping), below, ZNF695.
B) RT-PCR products run on a DNA Chip Agilent bioanalyzer. Top row: housekeeping gene RPL4. Middle and bottom rows: individual
transcripts of each of the differentially spliced mRNAs in malignant ovarian cancer tissue (MOT, n = 10) and individual ovarian cancer cell
lines (n = 4, shown by their names).
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identify in early stages as it goes asymptomatic over
long periods of time to be detectable only in late stages,
almost always beyond any possibility of remission [33,34].
Alternative exon splicing is a biological process of
major importance, because gene changes leading to al-
tered splicing can affect normal cell and tissue function
[19,20,27,35], including malignant transformation [36].
The current studies were carried out to examine whether
OC could be associated to particular exon-splicing state
and if so, to identify differentially spliced transcripts
present in OC but absent in healthy ovarian tissue. With
the exon array data set presented here, we identified
nine overexpressed genes with differential exon profiles
associated to OC, one such gene, ZNF695, coding for
a largely uncharacterized zinc finger protein, is the
most representative, with three transcripts differen-
tially expressed by MOT and OCL, one correspondingto the whole protein, a second ORF corresponding to a
shorter peptide and a third, with lower but significant
expression that corresponds to a long non-coding mRNA.
These results likely provide a useful biomarker of malignant
transformation in women suspected to have OC and open
the study of the role of these transcripts in cell proliferation
and malignant transformation.
Alternative splicing is a major source of protein diversity,
bioinformatics-based methods indicate that >90% human
genes could be subject to AS [10,12,13] with an estimate
of several million different proteins, and some individual
proteins having over 1000 variants due only to AS [37].
This process can differ during distinct cellular functional or
developmental stages [38,39]. It is, therefore, not surprising
that AS has also been found altered during malignant
transformation [40], which could be either a general marker
of cancer or limited to certain cancer types. Moreover,
cancer-associated AS could be the clue to understand the
Figure 5 Cloning and sequencing of novel ZNF695 transcripts associated to ovarian cancer. A) PCR product of ZNF695 showing the three
different RNA transcript sizes of ZNF695 expressed in malignant ovary tissue sample 6 (MOT6, right) and the individual amplicons used for cloning, with
the size (in base pairs) shown on the left. Ladder (line 1), ZNF695 splice variants 1 and/or 2 (lane 2, 400 bp), ZNF695 splice variant 4 (lane 3, 360 bp),
ZNF695 splice variant 5 (lane 4, 310 bp), and ZNF695 amplicons in MOT6 (line 5). B) Sanger sequence plot of ZNF695 splice variant 1 and 2 at the
boundary of exons 1 and 2. C) Sanger sequence plot of ZNF695 splice variant 1 and 2 at the boundary of exons 2 and 3. D) Sanger sequence plot of
ZNF695 splice 5. This transcript has alternative splicing in exon 1–2, with the arrow illustrating the alternative splicing site at the exon 1–2 boundary.
E) Sanger sequence plot of ZNF695 splice variant 4. This sequence has alternative site splicing in exon 2–3 (arrows), this sequence are contain in ZNF695
variant 5 too. F) AS model of ZNF695 gene. Black lines represent primary splicing of exons 1-2-3 of ZNF695 gene containing the full coding sequence that
corresponds to the largest amplicon. Green dotted line shows exons 2–3 AS, which corresponds to the intermediate amplicon. Red dotted line shows
exon 1 AS together with exons 2–3 AS, which are contained in the smaller amplicon.
Juárez-Méndez et al. Journal of Ovarian Research 2013, 6:61 Page 8 of 10
http://www.ovarianresearch.com/content/6/1/61basis of malignant transformation, tumor behavior [23,41],
and even for the identification of potential therapeutic
targets [42].
We found that OC tissue has indeed a signature of
alternatively spliced genes. Although we do not know
yet whether these changes are indeed related only to
OC or they are general markers of cancer. Of the >270
differentially spliced genes found in OC, nine were
highly significant, but we decided to focus on the most
significantly expressed gene with differential AS, the
zinc finger protein ZNF695.
The zinc finger protein family (ZNF) spans over 700
members with many functional roles within the cell,including regulation of gene expression, which is achieved
by different means. For instance, ZNF transcription factors
bind to DNA by means of C2H2 zinc finger domains,
constituting a subfamily of ZNF [43]. Although some
ZNF members act only as repressors, others solely as
act as activators, most of them can apparently be either
repressors or activators depending on the particular
status of the cell. Moreover, some ZNF play roles in
signal transduction and many other cellular functions.
ZNF695, which we found here to be differentially expressed
and spliced in OC belongs to the C2H2 subfamily of ZNF
and also contains Krüpple-associated box (KRAB) domains,
which characteristically identify gene repressors [44-46].
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more functional domains, changes affecting only one
domain can have dramatic consequences [45,47]. On
one hand, repressors could lose their regulatory function or
even turn in the opposite direction and become activators
[47]. KRAB domains in ZNF proteins serve to bind co-
repressors, which in turn mediate transcription repres-
sion [44]. Of the ZNF695 splice variants we found here
to be preferentially associated to OC, isoforms 2 and 3
have incomplete KRAB domains that are essential for
interactions with co-repressors which suggests that such
AS pattern could be related to carcinogenesis. The third
variant lacked the initial translation codon; hence, it is
unlikely to yield a translational product.
Unfortunately, as yet, almost nothing is known about
ZNF695 in humans or in other species, with the closest
homologues having up to 64% identity. Therefore, at
present it is not possible to predict how ZNF695 could
play a role in OC development, if at all. One could en-
vision that because the alternative forms found in OC
have incomplete KRAB domains, this potential repressor
could function as an activator and turn on cell proliferation
and, hence, malignant transformation. The other possibility
would be to function as dominant negative variants, but
this seems unlikely because normal ovarian tissue does not
express ZNF695 in any of its isoforms ad OC cells express
only the alternative splice variants. Therefore, we consider
ZNF695 splice variants 1/2, 4 and 5 as potential oncogenes
playing a role in the pathogenesis of OC.
Additional files
Additional file 1: Graphic showing the proportions of four
microarray quality controls. The Y-axis depicts the expression level of
controls (Log2) and the X- axis contains the 14 samples used for these
studies. A) Microarray hybridization controls where the purple line
corresponds to the control (CreX), green (BioDn), blue (BioC) red (BioB). B)
Microaray labelling controls: pink line (dab), brown (thr), blue (phe), and
orange controls (lys).
Additional file 2: Table of genes expressed in ovarian samples.
Additional file 3: Table of significantly over-expressed genes with
potential alternative splicing.
Additional file 4: Alignment of ZNF695 splice variants. BLAST
analysis of sequences obtained from the clones, alternatively spliced
ZNF695 variants found predominantly in malignant ovarian tissue and
cell lines. Transcript variant 1/2, the sequence corresponds to the heavier
band. ZNF695 Transcript variant 4, the sequence corresponds to the
medium sized band, and ZNF695 splice variant 5, this sequence
corresponds to the lighter band.
Additional file 5: Alignment of predicted ZNF695 peptides. In silico
translation of ZNF695 amplicons (ZNF695 transcript variant_1/2, ZNF695
transcript variant 4, ZNF695 transcript variant 5) revealing sequence
identity of unnamed protein product (BAG54313.1) with ZNF695
transcript variants 4 and 5. ZNF695 transcript variant 1/2 is identical to full
length ZNF695 (transcript variant 1 or 2).
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